**Bone Loss during Spaceflight: Available Models and Counter-Measures**

Jonathan Morris MD[1], David Bach[2], David Geller[1]

1. *Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA*
2. *Barrios Technology, LTD, NASA Lyndon B. Johnson Space Center, Houston, TX, USA*

There is ongoing concern for human health during spaceflights. Of particular interest is the uncoupling of bone remodeling and its resultant effect on calcium metabolism and bone loss. The calculated average loss of bone mineral density (BMD) is approximately 1-1.5% per month of spaceflight. The effect of decreased BMD on associated fractures in astronauts is not known. Currently on the International Space Station (ISS), bone loss is managed through dietary supplements and modifications and resistance exercise regimen. As the duration of space flights increases, a review of the current methods available for the prevention of bone loss is warranted. The goal of this project is to review and summarize recent studies that have focused on maintaining BMD during exposure to microgravity. Interventions were divided into physical (Table 1), nutritional (Table 2), or pharmacologic (Table 3) categories. Physical modalities included resistance exercise, low level vibration, and low intensity pulsed ultrasound. Nutritional interventions included altering protein, salt, and fat intake; and vitamin D supplementation. Pharmacologic interventions included the use of bisphosphonates and beta blockers. Studies reported outcomes based on bone density determined by DXA bone scan, micro-architecture of histology and microCT, and serum and urine markers of bone turnover. The ground analog models utilized to approximate osseous physiology in microgravity included human patients previously paralyzed or subjects confined to bedrest. Ground analog animal models include paralysis, immobilization and ovariectomies. As a result of the extensive research performed there is a multi-modality approach available for the management of BMD during spaceflight that includes resistance training, nutrition and dietary supplements. However, there is a paucity of literature describing a formalized tiered protocol to guide investigators through the progression from animal models to human patient ground analogs to experiments on the ISS. With regards to testing, further evaluation to determine the association between non-invasive tests and fracture during and after spaceflight needs to be performed.

| Physical Interventions | | | | | |
|---|---|---|---|---|---|
| **Intervention** | **Reference** | **Model** | **Number of Partcipipants** | **Outcome Measures** | **Results** |
| Resistance Exercise | Shackelford *et al*., 2004 | Human Bed Rest | 5 male, 4 female | Serum Markers | Resistance training exercise associated with increased bone turnover and formation markers vs control showing increase in resorption only |
| Low Level Vibration | Rubin *et al*., 2004 | Human Post Menopausal | 70 female | DXA | Intention-to-treat showed no change, however increased compliance associated with protective effect |
| LIPUS | Ferreri *et al*., 2011 | Ovariectomized Rats | 6 Groups of 5 animals each | MicroCT, FEA, Histology | Local improvement in microstructure, modulus of elasticity, strength, and bone volume with 100 $mW/cm^2$ |

Table 1. Studies examining physical interventions for the management of BMD. DXA = DXA Bone Scan, FEA = Finite Element Analysis, LIPUS = Low Intensity Pulsed Ultrasound

| Nurtritional Interventions | | | | | |
|---|---|---|---|---|---|
| **Intervention** | **Reference** | **Model** | **Number of Partcipipants** | **Marker** | **Results** |
| Decrease Sulfur containing Amino Acids | Breslau | Human Ambulatory | 15 healthy Individuals | Urine and Serum Markers | Increased sulfur containing amino acids associated with increased urince calcium |
| Limit NaCl intake | Buehlmeier *et al*., 2012 | Human Ambulatory | 8 healthy male | Urine and Serum Markers | Increased NaCl intake associated with increase in urine calcium excreted and NTX; counteracted with Potassium Bicarbonate |
| Omega-3-Fatty Acids | Zwart *et al*., 2010 | Bedrest, Short-duration Space Flight, Long Duration Space Flight | 10 Short Duration, 24 Long Duration, 16 Bedrest | Serum Markers | Increased fish intake assocaited with less bone loss in space |
| Vitamin D | Izawa *et al*., 1981 | Immobilized Rats | 48 animals | Bone length, Cortical thickness, Calcified bone mass | After 6 weeks Vitamin D analogs diminished the effect of immobilization in the development of osteoporosis |

Table 2. Studies examining nutritional interventions for the management of BMD

| Pharmacologic Interventions | | | | | |
|---|---|---|---|---|---|
| **Intervention** | **Reference** | **Model** | **Number of Partcipipants** | **Marker** | **Results** |
| Bisphosphonates: Aldendronate | LeBlanc *et al*., 2002 | Human Bedrest | 21 males | DXA, Serum Markers | Alendronate 70mg weekly showed positive effect of BMD |
| Bisphosphonates: Zoledronic Acid | Shapiro *et al*., 2004 | Spinal Cord Injury Patients | 15 patients | DXA | Single infusion of Zoledronic acid associated with protective effect on hip at 10 weeks |
| Bisphosphonates: Pamidronate | Watanabe *et al*., 2004 | Human Bedrest | 25 males | DXA, Serum Markers | Pamidronate vs Exercise vs Bedrest: Exercise increased bone formation, did not prevent bone loss; Pamidronate prevented bone loss |
| Propanolol | Khajuria *et al*., 2013 | Immobilized Rats | 5 groups of 6 animals each | Bone Porosity, Mechanical Properties, Electron Microscopy | Propanolol was comparable to Zoledronic acid and Alfacalcidol in regards to bone porosity, mechanical properties, and cortical microarchitecture |

Table 3. Studies examining pharmacologic interventions for the management of BMD